Acute myeloid leukemia trials in Spain

In Spain 62 Also abroad 761

62 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 1Not yet taking people in Spain
Bioavailability and Bioequivalence Study of Ziftomenib in Participants With Relapsed/Refractory AML or MDS
Where
Barcelona, Madrid, Oviedo, Sevilla, Valencia
Age
18 years and over
People
126 worldwide
Run by
Kura Oncology, Inc.
See details and how to joinNCT07929740 · EU 2025-524332-19-00
Phase 1Taking people
A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
Where
Barcelona, Madrid, Pamplona
People
225 worldwide
Run by
Janssen Cilag International
See details and how to join2026-525234-39-00 · EU 2026-525234-39-00
Phase 3Taking people
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
Where
Badalona, Barcelona, Girona, L'Hospitalet de Llobregat, Lleida, Madrid, Palma, Tarragona, Terrassa, Valencia
Age
18 years and over
People
875 worldwide
Run by
Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT07223814 · EU 2025-522767-15-00
Phase 1Taking people
A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML
Where
Cáceres, Madrid, Pamplona, Valencia
Age
18 years and over
People
40 worldwide
Run by
Charm Therapeutics
See details and how to joinNCT07751991 · EU 2026-526409-14-00
Phase 1/2Taking people
A first time in man study to look at the safety of the experimental drug CCS1477 and what effects it has on cancers that affect the blood, bone marrow, lymph and lymphatic system.
Where
Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Valencia
Age
18 years and over
People
16
Run by
Cellcentric Limited
See details and how to join2024-519498-20-00 · EU 2024-519498-20-00
Phase 1Enrolling by invitation
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Where
Barcelona, Madrid, Pamplona, Salamanca
Age
18 years and over
People
120 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06788509 · EU 2024-515457-21-00
Phase 1Taking people
First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)
Where
Barcelona, Madrid, Valencia
Age
18 years and over
People
78 worldwide
Run by
Genmab
See details and how to joinNCT07384715 · EU 2025-523101-15-00
Phase 3Taking people
Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)
Where
Albacete, Alcalá de Henares, Alicante, Almería, Badalona, Barakaldo, Burgos, Cáceres, Cadiz, Castelló, Córdoba, Donostia / San Sebastian, Hospitalet Del Llobregat, Huelva, Jaén, Las Palmas de Gran Canaria, Lugo, Madrid, Majadahonda, Málaga, Manresa, Murcia, Pamplona, Plasencia, Salamanca, San Sebastián de los Reyes, Santa Cruz de Tenerife, Santander, Santiago de Compostela, Segovia, Seville, Terrassa, Toledo, Valencia, Valladolid, Vigo
Age
18 years and over
People
376
Run by
PETHEMA Foundation
See details and how to joinNCT07478991
Phase 3Taking people
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Where
A Coruña, Barcelona, Cáceres, Jerez de la Frontera, L'Hospitalet de Llobregat, Madrid, Pamplona, Pozuelo de Alarcón, Salamanca, Santander, Seville, Valencia
Age
18 years and over
People
600 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06852222 · EU 2024-520154-38-00
Phase 3Taking people
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
Where
Barcelona, Granada, Las Palmas de Gran Canaria, Madrid, Salamanca, Valencia
Age
18 years to 75 years
People
366 worldwide
Run by
Priothera SAS
See details and how to joinNCT05429632
Phase 3Taking people
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
Where
Badalona, Barcelona, Cáceres, Málaga, Oviedo, Palma de Mallorca, Valencia
Age
18 years to 71 years
People
150 worldwide
Run by
Quetzal Therapeutics
See details and how to joinNCT07504458 · EU 2025-524810-28-00
No phaseTaking people
Master Framework For Relapse or Refractory Acute Myeloid Leukemia
Where
Valencia
Age
6 years and over
People
4,000 worldwide
Run by
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
See details and how to joinNCT06459024
Phase 3Taking people
IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.
Where
Albacete, Alicante, Barcelona, Valencia
Age
18 years and over
People
339 worldwide
Run by
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
See details and how to joinNCT06713837 · EU 2024-514517-35-00
Phase 3Taking people
A study to compare Venetoclax Azacitidine and Quizartinib Vs Venetoclax and Azacitidine in newly diagnosed acute myeloid leukemia patient´s ineligible for standard induction chemotherapy
Where
A Coruña, Albacete, Alcalá de Henares, Alicante, Almería, Badalona, Barakaldo, Barcelona, Bilbao, Burgos, Cáceres, Cadiz, Castello De La Plana, Córdoba, Donostia, Galdakao, Huelva, Jaén, Las Palmas de Gran Canaria, Las Palmas De Gran Canaria, L'Hospitalet de Llobregat, Lugo, Madrid, Majadahonda, Málaga, Manresa, Murcia, Palma, Pamplona, Plasencia, Pozuelo de Alarcón, Salamanca, San Cristóbal de La Laguna, San Sebastián de los Reyes, Santa Cruz de Tenerife, Santander, Santiago de Compostela, Segovia, Sevilla, Terrassa, Toledo, Valencia, Valladolid, Vigo, Vitoria, Zaragoza
Age
18 years and over
People
350
Run by
Fundacion PETHEMA
See details and how to join2025-522979-29-00 · EU 2025-522979-29-00
Phase 2/3Taking people
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
Where
Barcelona, L'Hospitalet de Llobregat, Madrid, Majadahonda, Pamplona, Sevilla, Valencia
Age
18 years and over
People
660 worldwide
Run by
AbbVie
See details and how to joinNCT07581002 · EU 2025-523724-47-00
Phase 3Taking people
A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia (AML) with a specific gene abnormality who have not previously been treated and who are not eligible for intensive chemotherapy.
Where
Badalona, Barcelona, Girona, Valencia
Age
18 years and over
People
180 worldwide
Run by
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
See details and how to join2024-512753-24-00 · EU 2024-512753-24-00
Phase 3Taking people
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
Where
Alcalá de Henares, Alicante, Badalona, Barcelona, Burgos, Cáceres, Granada, Las Palmas De Gran Canaria, L'Hospitalet de Llobregat, Madrid, Málaga, Oviedo, Palma, Pamplona, Pozuelo de Alarcón, Salamanca, Santander, Sevilla, Tarragona, Valencia
Age
12 years and over
People
468 worldwide
Run by
Syndax Pharmaceuticals
See details and how to joinNCT07211958 · EU 2025-522279-27-00
Phase 1Taking people
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML/HR-MDS and in Combination With Azacitidine in Previously Untreated HR-MDS
Where
Cáceres, Valencia
Age
18 years and over
People
105 worldwide
Run by
Stelexis BioSciences
See details and how to joinNCT06533761 · EU 2024-518071-58-00
Phase 3Taking people
Teicoplanin as Infection Prophylaxis in Pediatric Acute Myeloid Leukemia (Pro-Teico study)
Where
Alicante, Barcelona, Esplugues De Llobregat, Madrid, Málaga, Palma, Santiago De Compostela, Valencia, Zaragoza
Age
Up to 64 years
People
128 worldwide
Run by
Prinses Maxima Centrum voor Kinderoncologie B.V.
See details and how to join2023-506546-23-00 · EU 2023-506546-23-00
Phase 3Taking people
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Where
Albacete, Badalona, Barcelona, Burgos, Jaén, L'Hospitalet de Llobregat, Madrid, Oviedo, Salamanca, Sevilla, Valencia, Zaragoza
Age
18 years and over
People
1,300 worldwide
Run by
Kura Oncology, Inc.
See details and how to joinNCT07007312 · EU 2025-521314-25-00
Phase 1/2Taking people
Multi-centre Phase 1/2 study testing LB-208 for adults with relapsed/refractory AML or high-risk MDS
Where
Barcelona, Cáceres, Madrid, Oviedo, Pamplona, Valencia
Age
18 years and over
People
60
Run by
Aop Orphan Pharmaceuticals GmbH
See details and how to join2025-523396-38-00 · EU 2025-523396-38-00
Phase 1/2Taking people
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Where
Barcelona, Madrid, Valencia
Age
1 year to 17 years
People
70 worldwide
Run by
Incyte Biosciences International Sàrl
See details and how to joinNCT03934372 · EU 2023-509699-41-00
Phase 1/2Taking people
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Where
L'Hospitalet de Llobregat, Sevilla, Valencia
Age
30 days and over
People
447 worldwide
Run by
Syndax Pharmaceuticals
See details and how to joinNCT04065399 · EU 2024-513759-34-00
Phase 1Taking people
Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia
Where
Barcelona, Madrid
Age
0 years to 21 years
People
20 worldwide
Run by
PedAL BCU, LLC
See details and how to joinNCT06376162 · EU 2023-505262-28-00
No phaseNot yet taking people in Spain
Digital Patient-Reported Assessment in Older Adults With Acute Leukemia
Where
Oviedo
Age
65 years and over
People
20
Run by
Fundación para la Investigación Biosanitaria del Principado de Asturias
See details and how to joinNCT07597590